Condition
Maroteaux-Lamy Syndrome
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
200%
4 of 2 completed with results
Key Signals
4 with results50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (2)
P 4 (1)
Trial Status
Terminated2
Completed2
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02156674Not ApplicableTerminatedPrimary
Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome
NCT01043640Phase 2Completed
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
NCT00668564Phase 2Terminated
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
NCT00299000Phase 4Completed
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
Showing all 4 trials